Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Rafael resets after phase 3 flop, parting ways with 5 [...]
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?
AstraZeneca, after years of delays and spiraling costs, opens Cambridge [...]
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus
Vaccibody, now Nykode, celebrates new name with a Regeneron deal [...]
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
GlaxoSmithKline takes aim at NASH, penning a $1B pact with [...]
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen [...]
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Xencor finally finds buyer for onetime lead drug, offloading autoimmune [...]
New insights into how cancer cripples immune cells could fuel fresh I-O approaches
New insights into how cancer cripples immune cells could fuel [...]
Enanta dumps oral hep B program after safety warnings in early test
Enanta dumps oral hep B program after safety warnings in [...]
Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover preclinical cancer prospects
Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover [...]
Merck pauses ‘very important’ HIV program after seeing red flag in phase 2 trial of once-weekly combo
Merck pauses ‘very important’ HIV program after seeing red flag [...]